Results of Operations and Financial Condition. On August 5, 2026, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

President and Chief Executive Officer — Aziz Mottiwala: Aziz Mottiwala was appointed as President and Chief Executive Officer, replacing Ron Kurtz, M.D.

Entry into a Material Definitive Agreement. On June 30, 2026 (the “Effective Date”), we entered into a License, Collaboration and Development Agreement (the “RxSight-Alcon Collaboration Agreement”) with Alcon Pharmaceuticals, Ltd (“Alcon”), pursuant to which we will collaborate with Alcon to develop and commercialize light-adjustable versions of certain Alcon simultaneous vision intraocular lenses (“SVIOLs”) by incorporating RxSight Light Adjustable Technology™ (the “Collaboration Products”).…

Results of Operations and Financial Condition. On July 6, 2026, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited second quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under

and Item 9.01 (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Cautionary Note Regarding Forward-looking Statements This report contains for…

Results of Operations and Financial Condition. On May 6, 2026, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three months ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Chief Financial Officer — Mark Wilterding: Mr. Mark Wilterding was appointed as the Chief Financial Officer of RxSight, Inc.

Results of Operations and Financial Condition. On February 25, 2026, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Chief Financial Officer — Mark Wilterding: The company appointed an external candidate as the new Chief Financial Officer.

Results of Operations and Financial Condition. On January 11, 2026, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2025 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under

The report contains forward-looking statements and does not involve any management changes.

Chief Financial Officer — Shelley Thunen: Ms. Shelley Thunen is transitioning from her position as Chief Financial Officer with a consulting agreement in place.

Chief Business Development Officer, Chief Customer Officer — Eric Weinberg, Scott Gaines: Two internal promotions were made within the company.

Results of Operations and Financial Condition. On November 5, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and nine months ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Director — Raymond W. Cohen: Mr. Cohen was appointed to the Compensation Committee and Audit Committee of the Board.

Results of Operations and Financial Condition. On August 7, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Director — Raymond W. Cohen: Appointment of a new director with significant industry experience.

Results of Operations and Financial Condition. On July 8, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited second quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under

Results of Operations and Financial Condition. On May 7, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Results of Operations and Financial Condition. On April 2, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited first quarter financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under

Results of Operations and Financial Condition. On February 25, 2025, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and twelve months ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Results of Operations and Financial Condition. On January 12, 2025, RxSight, Inc. (the “Company”) issued a press release announcing certain preliminary unaudited fourth quarter and full-year 2024 financial and operational results. A copy of the press release is furnished herewith as Exhibit 99.1. In accordance with General Instruction B.2 of Form 8-K, the information furnished in this Current Report on Form 8-K under

Results of Operations and Financial Condition. On November 7, 2024, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and nine months ended September 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Results of Operations and Financial Condition. On August 5, 2024, RxSight, Inc. (the “ Company ” ) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The information furnished in this Current Report on Form 8-K under

Other Events. On May 8, 2024, the Company issued a press release announcing the pricing of the offering described above. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. In connection with such offering, the legal opinion as to the legality of the Common Stock sold is being filed as Exhibit 5.1 to this Current Report on Form 8-K and is incorporated herein and into the Registration Statement by reference. This Cur…